Expert Interview
A look at Roche's prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease and the published results from the Phase IIb PADOVA study.
Ticker(s): RHHBYInstitution: University of Louisville
- Professor of Neurology, Medical Geneticist, Endowed Chair of Parkinson’s Disease Research, & Director, Movement Disorders Program at University of Louisville.
- Manages 90 patients with Huntington's disease and 35 patients with Friedreich’s Ataxia.
- Research interests are focused on understanding the underlying genetic basis of hereditary spastic paraplegia and essential tremor; clinical interests include surgical therapies for Parkinson's disease, essential tremor and dystonia, and botulinum toxin procedures for dystonia and spasticity.
Based on the PADOVA study results, how meaningful do you find the slowing of motor progression with prasinezumab in early Parkinson’s—particularly compared to the current standard of care?
Added By: sara_adminHow confident are you in alpha-synuclein as a disease-modifying target in Parkinson’s, and does the prasinezumab data shift your thinking around the role of immunotherapy in early-stage treatment?
Added By: sara_adminIf prasinezumab advances toward approval, what would you need to see in Phase III to feel confident incorporating it into your treatment strategy for early-stage patients?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
